Effect of therapy with rosuvastatin on circulating endothelial progenitor cells in patients with chronic heart failure

Kardiologiya

Volumn 49, Issue 5, 2009, Pages 11-15

  Moiseeva, O M ^a   Karelkina, E V ^a   Moroshkin, V S ^a   Selyutin, A V ^a   Slyakhto, E V ^a  

^a NONE

Author keywords

Circulating endothelial progenitor cells; Heart failure; Rosuvastatin.

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; FLUOROBENZENE; GLYCOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOCYTE ANTIGEN; PEPTIDE; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

ADULT; ARTICLE; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART FAILURE; HEART STROKE VOLUME; HUMAN; IMMUNOLOGY; MALE; MESENCHYMAL STEM CELL; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ADULT; ANTIGENS, CD; ANTIGENS, CD34; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; GLYCOPROTEINS; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; PEPTIDES; PYRIMIDINES; STROKE VOLUME; SULFONAMIDES; TREATMENT OUTCOME;

EID: 70249086312     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hilfiker-Kleiner D., Landmesser U., Drexler H. Molecular mechanisms in heart failure: focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardio 2006;48:A56-A66. (Pubitemid 44648642)
2. Stefanec T. Endothelial apoptosis:could it have a role in the pathogenesis and treatment of disease. Chest 2000; 117:841-854. (Pubitemid 30152229)
3. Le Noble F A.C., Stassen F.R.M., Hacking W.J.G. et al. Angiogenesis and hypertension. J Hypertens 1998; 16: 1563-1572.
4. Isner J.M.,Asahara T.Angiogenesis and vasculogenesisastherapeutic strategies for postnatal neovascularization. J Clin Invest 1999; 103: 1231-1236. (Pubitemid 29218292)
5. BrunnerH., Cockcroft J.R., Deanfield J. et al. Endothelial function and dysfunction. Part II:Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:233-246. (Pubitemid 40279622)
6. Urbich C., DimmelerS. Endothelial progenitorcells: characterization and role in Vascular Biology. Ore Res 2004;95:343-353. (Pubitemid 39100452)
7. Hill J.M., Zalos G., Hakox J.P.J, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600. (Pubitemid 36204953)
8. Werner N., Kosiol S., Schiegl T. et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007. (Pubitemid 41262334)
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
10. Asahara T., Murohara T., Sullivan A. et al. Isolation of putative endothelial progenitor cells for angiogenesis. Science 1997;275:964-967. (Pubitemid 27087709)
11. Urbich C.,Dimmeler St. Endothelial progenitorcells. Characterization and role in vascular biology. Cir Res 2004;95:343-353. (Pubitemid 39100452)
12. Gu″ven H., Shepherd R.M., Bach R.G. et al. The number of endothelial progenitor cell colonies in the blood is increased in patients with angiographically significant coronary artery disease. J Am Coll Cardiol 2006; 48: 1579-1587.
13. Shintani S., Murohara T., Ikeda H. et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001;103:2776-2779. (Pubitemid 32550062)
14. Umemura T., Higashi Yu. Endothelial progenitor cells:therapeutic target for cardiovascular disease. J Pharmacol Sci 2008; 108: 1-6.
15. Kenchaiah S., Pocock S.J., Wang D. et al. Body mass index and prognosis in patients with Chronic Heart Failure insights from the candesartan in heart failure:assessment of reduction in mortality and morbidity (CHARM) program. Circulation 2007; 116:627-636. (Pubitemid 47356347)
16. Hoetzer G.L., Van Guilder G.P., Irmiger H.M. et al. Aging, exercise, and endothelial progenitor cell clonogenic and migratory capacity in men. Appl Physiol 2007:102:847-852. (Pubitemid 46377004)
17. Detva P., Degan M., Vallerio P. et al. Endothelial progenitor cells in patients with essential hypertension. J Hypertens 2007;25:127-132. (Pubitemid 44885673)
18. Mills E.J., Rachlis B., Wu P. et al. Prevention of cardiovascular mortality and events with statin treatments. J Am Coll Cardiol 2008; 52: 1769-1781.
19. Rauchhaus M., Koloczek V., Volk H. et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 2000; 76: 125-133.
20. Van der Harst P. et al. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 2006; 71: 443-454.
21. Fukuta H. et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure. Circulation 2005; 112: 357-363.
22. Saijonmaa O., Nyman T., Stewen P., Fyhrquist F. Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. Am J Physiol Heart Circ Physiol 2004;286:H2096-H2102. (Pubitemid 38685222)
23. Zoghbi G.J., Dorfman T.A., Iskandrian A.M. The effects of medications on myocardial perfusion J Am Coll Cardiol 2008;52:401-416. (Pubitemid 352040813)
24. Verma S., Kuliszewski M.A., Shu-Hong Li. et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation and function. Circulation 2004; 109: 2058-2067.
25. Spiel A.O., Mayr F.B., Leitner J.M. et al. Simvastatin and rosuvastatin mobilize endothelial progenitor cells but do not prevent their acute decrease during systemic inflammation. Thromb Res 2008; 123: 108-113.
26. George J., Goldstein E. Abashidie S. et al. Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation Eur Heart J 2004;25:1003-1008. (Pubitemid 38869417)
27. Timmermans F., Van Hauwermeiren F., De Smedt M. et al. Endothelial outgrowth cells are not derived from CD 133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vase Biol 2007;27:1572-1579. (Pubitemid 46986112)
28. Zampetaki A., Kirton J.P., Xu Q. Vascular repair by endothelial progenitor cells. Cardiovasc Res 2008;78:413-421. (Pubitemid 351769775)
29. Zengin E., Chalajour F., Gehling U.M. et al. Vascular wall resident progenitor cells:a source for postnatal vasculogenesis. Development 2006; 133:1543-1551. (Pubitemid 43732967)
30. Llevadot J., Murasawa S., Kureishi Y. et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001, 108:399-405. (Pubitemid 32730786)
31. Vasa M., Fichtischerer S., Adler K. et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-2890. (Pubitemid 32578123)
32. Boodhwani M., Nakai Y., Voisine P. et al. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation 2006; 114: 1402-1408.
33. Nissen S.E. et al. forthe REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004;291:1071-1080. (Pubitemid 38541684)
34. Kusuyama T., Omura T., Nishiya D. et al. The effects of HMGCoA reductase inhibitor on vascular progenitor cells. J Pharmacol Sci 2006;101:344-349. (Pubitemid 44285183)
35. Zoll J., Fontaine V., Gourdy P. et al. Role of human smooth muscle cell progenitors in atherosclerotic plaque development and composition. Cardiovasc res 2008;77:471-480. (Pubitemid 351197652)
36. Dimmeler St., Aicher A., Vasa M. et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase. Akt pathway. J Clin Invest 2001;108:391-397. (Pubitemid 32730785)
37. Kjekshus J., Apetrei E., Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261. (Pubitemid 350190755)